Compare Clorox Co (CLX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs Viatris Inc — how do they compare? Clorox Co trades at $105.95 (market cap $13.09B), while Viatris Inc trades at $16.23 (market cap $18.69B). The key difference: Viatris Inc is the larger of the two by market cap, and Clorox Co pays the higher dividend (4.62%). Which is the better fit depends on your goals.
| CLX | VTRS | |
|---|---|---|
Market Cap | $13.09B | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $127.16 | $17.86 |
52-Week Low | $86.12 | $9.49 |
Enterprise Value | $18.47B | $30.80B |
Dividend Yield | 4.62% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLX trades at $106.30, down 1.3% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $1.66, though Q4 2025 missed. The company reported FY2025 revenue of $7.10B and net income of $810M, with improving margins. A dividend increase to $1.25 per share was announced, payable in August 2026.
Outlook is mixed: strong profitability and dividend support value, but high P/E of 22.51 and modest revenue growth pose valuation concerns. Analyst consensus is cautious with a $97.50 price target below current levels. Risks include inflation pressures and competitive threats from private labels, limiting near-term upside potential.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
